Fosamax and Osteonecrosis of the Jaw: Scientific Evidence of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Science to Medication Safety

The legacy context of general health and science information has long provided a foundation for understanding broad wellness principles and disease prevention. Within this framework, public awareness of medication safety and adverse effects has been a consistent theme, emphasizing the importance of evidence-based knowledge for informed health decisions. This heritage naturally extends to examining specific pharmaceutical agents and their potential risks, particularly when long-term use may be associated with serious conditions. One such area of focus involves bisphosphonate medications, commonly prescribed for bone-related disorders, and their possible link to osteonecrosis of the jaw. The transition from general health education to this specific concern requires careful consideration of exposure patterns, especially in occupational settings where individuals may encounter these compounds through manufacturing, handling, or environmental contamination. The pivot to occupational exposure concern is grounded in the principle that workplace environments can present unique risks distinct from therapeutic use. Thus, the discussion moves from a broad health science perspective to a targeted inquiry into how occupational contact with bisphosphonates might contribute to jaw bone complications, without delving into mechanistic details or citing specific evidence. This shift underscores the need for vigilance in industrial hygiene and worker safety protocols.

Bridging Occupational Exposure to Clinical Evidence

While occupational exposure to bisphosphonates is a distinct concern, the scientific evidence connecting these compounds to osteonecrosis of the jaw (ONJ) primarily derives from clinical and pharmacological studies of therapeutic use. Fosamax (alendronate) is a bisphosphonate approved for osteoporosis and other bone conditions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a serious adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw. This condition is characterized by exposed, non-healing bone in the maxillofacial region, often presenting with pain, swelling, infection, and delayed healing after dental procedures. Diagnosis is based on clinical examination and imaging, with necrotic bone in the oral cavity being a key feature. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Pharmacological Mechanisms Linking Fosamax to ONJ

The scientific evidence connecting Fosamax to ONJ is supported by pharmacological and mechanistic pathways. Bisphosphonates like alendronate accumulate in bone, particularly in areas of high turnover such as the jaw. They inhibit osteoclast activity, which reduces bone remodeling. This suppression of normal bone turnover can impair the jawbone's ability to repair microdamage and respond to local stressors, such as dental infections or trauma. Multiscale characterization of jawbone in animal models treated with bisphosphonates has provided insights into these effects. In estrogen-deficient rats, treatment with alendronate (ALN) was studied to determine its effect on jawbone properties, including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). Such research helps understand jawbone-specific responses to bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). The mechanistic pathway involves bisphosphonate-induced inhibition of angiogenesis, alteration of immune responses, and direct toxicity to oral epithelial cells, all of which contribute to compromised healing and necrosis.

Risk Considerations and Adequacy of Warnings

Regarding risk considerations, the adequacy of warnings about Fosamax and ONJ is addressed in prescribing information. The label explicitly states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It notes that the risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These warnings are part of the drug's safety information, but their adequacy depends on whether patients and healthcare providers are fully informed about the risk, especially given that ONJ can occur spontaneously or after dental procedures.

Causation and Temporal Relationship

Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax exposure and the development of ONJ. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal link, as the condition improves upon discontinuation and recurs upon re-exposure. However, in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating that not all cases are attributable to the drug and that other factors, such as underlying dental disease or procedures, play a role. The timeline between exposure and documented harm can vary widely. ONJ may develop after months or years of bisphosphonate use, and the risk increases with longer exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients on Fosamax for osteoporosis, the optimal duration of use has not been determined, and for low-risk patients, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This recommendation reflects the balance between fracture prevention and the risk of adverse effects like ONJ.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ) and how is it diagnosed?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves areas of exposed bone that persist for weeks to months, often accompanied by pain, swelling, infection, and delayed healing after dental procedures. Diagnosis is based on clinical examination and imaging, with a key feature being the presence of necrotic bone in the oral cavity. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is the scientific evidence linking Fosamax to ONJ?

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.